A CLINICAL STAGE COMPANY WITH PRODUCTS FOR THE

TREATMENT OF CANCER AND CARDIAC SIDE EFFECTS

See What We do

MITIGATION OF CARDIAC SIDE EFFECTS

Signpath has developed a platform technology aimed at mitigating cardiac side effects of other drugs, including cardiac arrhythmia and cardiac damage associated with chemotherapy.

Learn More

LIPOSOMAL CURCUMIN FOR TREATMENT OF CANCER

Signpath is conducting clinical trials in a proprietary liposomal formulation of curcumin. Signpath’s liposomal formulation allows for curcumin to be administered intravenously and provides for active and sustained levels of curcumin that are over 1000 times greater than traditional oral curcumin administration. Signpath is initially targeting multiple myeloma and glioblastoma.

Learn More

The CorreQT Technology Platform

Signpath’s patented CorreQT technology allows us to create new, cardiac safe versions of existing drugs. The lead CorreQT compound in development is SPP4040, a lipid-based drug which is administered orally. SPP4040 eliminates the dangerous cardiac arrhythmia which is a common side effect of many other drugs. The CorreQT platform allows Signpath to create patented, next generation drugs with improved cardiac safety across multiple classes, including anti-cancer agents, antibiotics, antipsychotics, antihistamines and others.

An Innovative Immuno-Oncology Agent with Minimal Side Effects

LipoCurc, Signpath’s patented Liposomal Curcumin product, was developed by researchers at the M.D. Anderson Cancer center, and exclusively licensed to Signpath. LipoCurc has completed Phase I human trials, exhibiting both efficacy and minimal toxicity at clinical doses. LipoCurc’s unique combination of mechanism pathways action includes inhibiting cancer checkpoint molecules that suppress the body’s immune response, as well as suppression of TNF alpha, IL-1 beta, IL-6, and Interferon gamma.

About SignPath

Signpath Pharma is headquartered in Sandy, Utah (a suburb of Salt Lake City.) We have partnerships and working relationships with labs, hospitals, and other companies in Canada, Europe, the U.S., and Asia.

Established in 2007 with the goal of developing Curcumin for cancer treatment, Signpath has since expanded into the area of cardiology, specifically the mitigation of pharmaceutical cardiac side effects.

We are committed to bringing innovative new treatments through the clinic and into the marketplace, addressing significant unmet medical needs.

More About Us